📊 SCYX Key Takeaways
Is Scynexis Inc. (SCYX) a Good Investment?
SCYX is a pre-revenue pharmaceutical company with accelerating losses and negative cash burn of $8.1M quarterly, providing only ~4.5 quarters of runway despite improving loss trends. The company must achieve product commercialization or secure additional funding imminently; zero revenue in a pharma sector indicates either developmental delay, failed trials, or a transitional crisis.
Scynexis Inc. Key Strengths (SCYX)
- Strong liquidity position with 3.94x current ratio and $36.7M cash reserves
- Manageable debt leverage at 0.84x debt-to-equity ratio
- Improving loss trajectory with 59.6% YoY improvement in net income indicating potential operational progress
SCYX Stock Risks: Scynexis Inc. Investment Risks
- Zero revenue indicates no commercial product traction or active market presence in pharmaceutical sector
- Negative operating cash flow of -$8.1M quarterly with limited cash runway of approximately 1+ years at current burn rate
- Significant operating losses of -$16.9M with no clear visibility to profitability or revenue generation
- High-risk pharma sector dependency on successful drug development, regulatory approval, and clinical outcomes
Key Metrics to Watch
- Revenue recognition and first product commercialization milestones
- Operating cash burn rate and cash runway extension
- Clinical trial progress, FDA approval status, and product pipeline advancement
Scynexis Inc. (SCYX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.94x current ratio provides a solid financial cushion.
SCYX Profit Margin, ROE & Profitability Analysis
SCYX vs Healthcare Sector: How Scynexis Inc. Compares
How Scynexis Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Scynexis Inc. Stock Overvalued? SCYX Valuation Analysis 2026
Based on fundamental analysis, Scynexis Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Scynexis Inc. Balance Sheet: SCYX Debt, Cash & Liquidity
SCYX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Scynexis Inc.'s revenue has grown significantly by 57% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.44 indicates the company is currently unprofitable.
SCYX Revenue Growth, EPS Growth & YoY Performance
SCYX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$5.4M | $-0.11 |
| Q3 2025 | $334.0K | -$2.8M | $-0.06 |
| Q2 2025 | $736.0K | -$6.9M | $-0.14 |
| Q1 2025 | $257.0K | $411.0K | $0.01 |
| Q3 2024 | $660.0K | -$1.8M | $-0.04 |
| Q2 2024 | $736.0K | -$14.0M | $-0.29 |
| Q1 2024 | $1.1M | $411.0K | $0.01 |
| Q3 2023 | $1.6M | -$1.8M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Scynexis Inc. Dividends, Buybacks & Capital Allocation
SCYX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Scynexis Inc. (CIK: 0001178253)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SCYX
What is the AI rating for SCYX?
Scynexis Inc. (SCYX) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SCYX's key strengths?
Claude: Strong liquidity position with 3.94x current ratio and $36.7M cash reserves. Manageable debt leverage at 0.84x debt-to-equity ratio.
What are the risks of investing in SCYX?
Claude: Zero revenue indicates no commercial product traction or active market presence in pharmaceutical sector. Negative operating cash flow of -$8.1M quarterly with limited cash runway of approximately 1+ years at current burn rate.
What is SCYX's revenue and growth?
Scynexis Inc. reported revenue of $0.0.
Does SCYX pay dividends?
Scynexis Inc. does not currently pay dividends.
Where can I find SCYX SEC filings?
Official SEC filings for Scynexis Inc. (CIK: 0001178253) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SCYX's EPS?
Scynexis Inc. has a diluted EPS of $-0.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SCYX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Scynexis Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SCYX stock overvalued or undervalued?
Valuation metrics for SCYX: ROE of -51.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SCYX's AI grade for 2026?
Our dual AI analysis gives Scynexis Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SCYX's free cash flow?
Scynexis Inc.'s operating cash flow is $-8.1M, with capital expenditures of $0.0.
How does SCYX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -51.6% (avg: 15%), current ratio 3.94 (avg: 2).